◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Sunshine Lake Pharma Co., Ltd. (6887) Financial History

Name: Sunshine Lake Pharma Co., Ltd. (6887) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-10

Sunshine Lake Pharma Co., Ltd. (6887) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Dongguan, China with about 6,353 employees. Its market capitalization is roughly CNY 20 billion. In the fiscal year ended 2025-12-31, 6887 reported CNY 4.8B in revenue and CNY 272M in net income.

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien and Dongyinghe for the treatment of hepatitis C.

Interactive charts & full statements →

6887 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CNY 4.8B	CNY 4.0B	CNY 6.4B	CNY 3.8B
Gross Profit	CNY 3.7B	CNY 3.1B	CNY 5.1B	CNY 2.9B
Operating Income (EBIT)	CNY 631M	CNY 485M	CNY 2.2B	CNY 557M
Net Income	CNY 272M	(CNY 207M)	CNY 185M	(CNY 1.2B)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6887 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Dividends Paid	(CNY 584M)	—	—	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6887 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Assets	CNY 12.0B	CNY 11.9B	CNY 12.7B	CNY 10.7B
Total Liabilities	CNY 7.7B	CNY 7.5B	CNY 8.5B	CNY 11.6B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6887 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

HLN · Haleon plc — $31 billion
3320 · China Resources Pharmaceutical Group Limited — $30 billion
0867 · China Medical System Holdings Limited — $30 billion
1513 · Livzon Pharmaceutical Group Inc. — $23 billion
0512 · Grand Pharmaceutical Group Limited — $19 billion
4538 · Fuso Pharmaceutical Industries,Ltd. — $19 billion
3933 · The United Laboratories International Holdings Limited — $18 billion
0013 · HUTCHMED (China) Limited — $17 billion

← 6886 All “0-9” companies 6888 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.